CooperCompanies to Present at the J.P. Morgan Healthcare Conference
Rhea-AI Summary
CooperCompanies (Nasdaq: COO) will present at the J.P. Morgan Healthcare Conference on January 14, 2026. Al White, President and CEO, is scheduled to speak in a session beginning at 5:15pm ET. A live and archived webcast will be available on CooperCompanies' investor website for those who cannot attend the session in person.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, COO gained 0.33%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed, mostly modest moves: BAX +1.57%, SOLV +0.26%, RMD +0.19%, WST -0.68%, HOLX 0.00%, while COO was roughly flat at +0.06%, pointing to stock-specific rather than broad sector activity.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Board cooperation deal | Neutral | -1.1% | Added independent director and cooperation agreement with Browning West. |
| Dec 04 | Board & review update | Positive | +1.7% | New Board Chair and strategic review with focus on $2B buyback. |
| Dec 04 | Earnings and guidance | Positive | +1.7% | Q4 and FY 2025 results with guidance and free cash flow goals. |
| Nov 04 | Earnings date notice | Neutral | -0.3% | Announced date and time for Q4 and full-year 2025 results. |
| Oct 01 | Awareness campaign support | Neutral | -0.7% | Support for Canadian optometry campaign on children’s myopia awareness. |
Recent price reactions tended to be modest, with positive moves on earnings and strategic review news, and small declines on neutral operational or awareness updates.
Over the past few months, CooperCompanies has reported solid fiscal 2025 results with revenue of $4,092.4M and non-GAAP EPS of $4.13, plus guidance and a long-term free cash flow objective above $2.2B. Governance actions included appointing a new Board Chair effective January 2, 2026 and launching a strategic review alongside a $2B repurchase program. The latest conference participation announcement fits within this cadence of ongoing investor communications rather than marking a new financial or strategic inflection point.
Market Pulse Summary
This announcement signals planned investor outreach as CooperCompanies presents at a major healthcare conference on January 14, 2026 at 5:15pm ET. It follows recent milestones including fiscal 2025 results, a strategic review, and governance changes. With shares trading above the 200-day MA yet below the 52-week high, investors may focus on any new strategic or financial details shared during the webcast and how they relate to prior guidance and capital allocation plans.
AI-generated analysis. Not financial advice.
SAN RAMON, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will participate at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Al White, President and CEO, will represent the Company in a session scheduled to begin at 5:15pm ET.
A live and archived webcast of the event, where applicable, will be available on the CooperCompanies’ website at http://investor.coopercos.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com